Rituximab combined with omalizumab (DrugBank: Omalizumab, Rituximab)
7 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
46 | 悪性関節リウマチ | 0 |
53 | シェーグレン症候群 | 0 |
65 | 原発性免疫不全症候群 | 0 |
98 | 好酸球性消化管疾患 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 1 |
226 | 間質性膀胱炎(ハンナ型) | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04128176 (ClinicalTrials.gov) | May 25, 2021 | 12/10/2019 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab combined with Omalizumab | University of California, Davis | NULL | Not yet recruiting | 18 Years | 90 Years | All | 15 | Phase 3 | United States |